Figure 1.

Schematic representation of the therapeutic schedule and biological sample collection. The therapeutic strategy was based on a sequence of therapeutic cycles performed every 3 weeks up to cycle 4 (C4) and every 4 weeks thereafter for a further 2 cycles, up to a maximum of 6 months of treatment. At the first (C1) and third (C3) cycle, the administration of high-dose interleukin-2 (HD IL-2) was preceded by radiotherapy. The second (C2), the fourth (C4), the fifth (C5) and the sixth (C6) cycles consisted in the administration of HD IL-2 only. Biological samples were collected at established times during the treatment.